Multiple sclerosis (MS) white matter lesions are inflammatory-demyelinating (WM-ID) and perivenular whereas white matter lesions of primary small vessel disease migraine and systemic autoimmune diseases with neurological involvement are mainly ischemic and periarteriolar. In MS the “central vein (CV) sign" that can be visualized by T2* MRI sequences, is present in about 75% of the WM-ID lesions. In the other diseases the frequency is lower than 50%. In this study the CVsign was compared in definite MS and in MS patients with markers of “better explanation” of the diagnosis (MS-like), for evaluating differences in the pathogenic mechanisms. The CVsign can identify pathogenesis of most the MS–like patients.

Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis / M., Grammatico; Dallagiacoma, S.; Lorenzoni, L.; Carlucci, G.; Repice, A. M.; Mechi, C.; Magnani, E.; Vuolo, L.; Fainardi, E.; Massacesi, L.. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - STAMPA. - 24:(2017), pp. 575-575.

Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis.

M. Grammatico
;
DALLAGIACOMA, STEFANIA;LORENZONI, LAURA LUNA;G. Carlucci;A. M. Repice;C. Mechi;E. Magnani;L. Vuolo;E. Fainardi;L. Massacesi
2017

Abstract

Multiple sclerosis (MS) white matter lesions are inflammatory-demyelinating (WM-ID) and perivenular whereas white matter lesions of primary small vessel disease migraine and systemic autoimmune diseases with neurological involvement are mainly ischemic and periarteriolar. In MS the “central vein (CV) sign" that can be visualized by T2* MRI sequences, is present in about 75% of the WM-ID lesions. In the other diseases the frequency is lower than 50%. In this study the CVsign was compared in definite MS and in MS patients with markers of “better explanation” of the diagnosis (MS-like), for evaluating differences in the pathogenic mechanisms. The CVsign can identify pathogenesis of most the MS–like patients.
2017
Goal 3: Good health and well-being for people
M., Grammatico; Dallagiacoma, S.; Lorenzoni, L.; Carlucci, G.; Repice, A. M.; Mechi, C.; Magnani, E.; Vuolo, L.; Fainardi, E.; Massacesi, L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1108934
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact